ARK Genomic Revolution ETF vs Micron Technology, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $41.24, while Micron Technology, Inc. trades at $925 (market cap $1.11T). The key difference: Micron Technology, Inc. pays a 0.05% dividend while ARK Genomic Revolution ETF pays none. Which is the better fit depends on your goals.
| ARKG | MU | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $43.57 | $1.21K |
52-Week Low | $23.09 | $104.88 |
Market Cap | — | $1.11T |
Enterprise Value | — | $1.09T |
Dividend Yield | — | 0.05% |
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
Micron Technology (MU) trades at $979.30, down 1.24% on the day, with strong technical support near $974 and bullish moving average signals. The company demonstrates exceptional fundamental strength with Q1 2026 EPS of $25.11 beating expectations by 20%, robust 55.91% net income margins, and accelerating revenue growth from $37.38B in 2025 to projected $90.3B in 2026. Recent news highlights the company's $250 billion AI memory investment and leadership in the semiconductor shortage cycle.
Outlook remains positive with 81% analyst buy ratings and $1,540 consensus price target representing 57% upside. Key opportunities include AI memory demand and humanoid robotics growth, while risks involve cyclical semiconductor exposure and competitive pressure from SK Hynix's Nasdaq debut. The stock presents a compelling growth story with strong earnings momentum and institutional support.
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →